Analysts Offer Predictions for VKTX Q4 Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Stock analysts at B. Riley issued their Q4 2024 earnings per share estimates for Viking Therapeutics in a research note issued to investors on Thursday, November 21st. B. Riley analyst M. Mamtani expects that the biotechnology company will earn ($0.24) per share for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($0.98) per share. B. Riley also issued estimates for Viking Therapeutics’ Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.23) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($2.53) EPS and FY2028 earnings at ($1.83) EPS.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Wednesday, October 23rd. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.02. During the same period in the previous year, the business posted ($0.23) earnings per share.

Other research analysts also recently issued research reports about the stock. StockNews.com upgraded shares of Viking Therapeutics to a “sell” rating in a research report on Tuesday, October 15th. Oppenheimer reaffirmed an “outperform” rating and issued a $138.00 price target on shares of Viking Therapeutics in a report on Wednesday, September 25th. William Blair reissued an “outperform” rating on shares of Viking Therapeutics in a report on Wednesday, November 20th. JPMorgan Chase & Co. initiated coverage on Viking Therapeutics in a research note on Wednesday, September 11th. They set an “overweight” rating and a $80.00 target price for the company. Finally, HC Wainwright boosted their price target on shares of Viking Therapeutics from $90.00 to $102.00 and gave the stock a “buy” rating in a report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $109.73.

Viking Therapeutics Price Performance

VKTX opened at $51.99 on Monday. The firm has a fifty day moving average price of $63.43 and a 200 day moving average price of $60.05. Viking Therapeutics has a 1 year low of $11.55 and a 1 year high of $99.41. The stock has a market cap of $5.79 billion, a P/E ratio of -55.90 and a beta of 1.00.

Institutional Investors Weigh In On Viking Therapeutics

A number of hedge funds have recently modified their holdings of VKTX. Tidal Investments LLC boosted its holdings in Viking Therapeutics by 296.8% in the 3rd quarter. Tidal Investments LLC now owns 15,190 shares of the biotechnology company’s stock valued at $962,000 after purchasing an additional 11,362 shares during the last quarter. World Investment Advisors LLC purchased a new stake in shares of Viking Therapeutics during the 3rd quarter valued at approximately $240,000. Sanctuary Advisors LLC lifted its holdings in Viking Therapeutics by 51.3% in the third quarter. Sanctuary Advisors LLC now owns 5,416 shares of the biotechnology company’s stock valued at $343,000 after acquiring an additional 1,836 shares during the last quarter. Second Line Capital LLC grew its position in Viking Therapeutics by 34.1% in the third quarter. Second Line Capital LLC now owns 38,118 shares of the biotechnology company’s stock worth $2,413,000 after acquiring an additional 9,699 shares during the period. Finally, Vestcor Inc acquired a new stake in Viking Therapeutics during the third quarter worth $741,000. Hedge funds and other institutional investors own 76.03% of the company’s stock.

Insider Transactions at Viking Therapeutics

In other Viking Therapeutics news, Director J Matthew Singleton sold 10,300 shares of the company’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $69.50, for a total value of $715,850.00. Following the completion of the sale, the director now directly owns 9,500 shares in the company, valued at $660,250. This represents a 52.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lawson Macartney sold 2,000 shares of Viking Therapeutics stock in a transaction on Friday, November 8th. The stock was sold at an average price of $68.67, for a total value of $137,340.00. Following the transaction, the director now owns 47,965 shares in the company, valued at approximately $3,293,756.55. This represents a 4.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 371,117 shares of company stock valued at $27,140,009. Corporate insiders own 4.70% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.